Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL OILY versus IOPAMIDOL 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL OILY versus IOPAMIDOL 200.
DIONOSIL OILY vs IOPAMIDOL-200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL OILY is a radiographic contrast agent containing propyliodone, which is an iodine-containing compound that absorbs X-rays, thereby enhancing the visualization of body structures during imaging procedures.
Iopamidol is a nonionic iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It does not have a pharmacological effect but provides radiographic opacity.
Adults: 10 mL intraurethral instillation as a sterile oily suspension (50% w/v) once daily for 3-5 days.
Intravascular: 50-150 mL (75-225 mg iodine/kg) IV; frequency depends on procedure, usually single dose. Intrathecal: 5-15 mL (200 mg iodine/mL) injected into subarachnoid space.
None Documented
None Documented
Terminal elimination half-life of the iodine moiety is approximately 60 days due to slow release from fatty tissues. This long half-life reflects the persistence of the oily vehicle and slow deiodination, necessitating monitoring for cumulative iodine effects.
Terminal half-life: 2 hours (normal renal function); prolonged to 8-48 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of the water-soluble metabolite (propiodone) after hepatic deiodination; approximately 60-80% of the administered iodine is excreted in urine within 48 hours. Fecal excretion is negligible (<5%).
Renal: >95% unchanged via glomerular filtration within 24 hours; biliary/fecal: <1%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent